Synektik Sa · GPW:SNT

Synektik Sa — Q1 FY2025 Earnings Presentation

24 slides from Synektik Sa's earnings presentation, February 2026

  1. Slide 1: Q1 FY 2025: Financial results

    SYNEKTIK SA Q1 FY 2025: Financial results Investor Presentation February 2026 Q1 FY 2025 Financial results | Investor presentation 1

  2. Slide 2: Synektik in snapshot

    Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 228m 60m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 2.55bn REVENUE FROM SALES, EBITDA FROM CONTINUING Enterprise value(2) PLN 2.42bn Q1 FY2025 OPERATIONS Q1 FY2025 P/E(3) 19.2 EV/EBITDA(4) 12.9 Company profi

  3. Slide 3: Highlights

    Highlights Sales of equipment and IT solutions – revenue growth and business expansion  PLN 214.1 million in revenue (excluding intra-group transactions) in Q1 FY2025 (12% increase), including PLN 91.2 million in recurring revenue (34% year- on-year growth); segment EBITDA of PLN 60.6 million (20%

  4. Slide 4: Financial performance in Q1 FY2025 (PLN mln)

    Financial performance in Q1 FY2025 (PLN mln) Consolidated revenue  12% increase in total revenue from sales of equipment, IT solutions and Q1 FY2025 228.0 services (excluding intra-group transactions) +12% Q1 FY2024 203.1  15% increase in revenue of the radiopharmaceuticals segment, excluding intr

  5. Slide 5: Group's adjusted EBITDA in FY 2022-2025

    Group’s adjusted* EBITDA in FY 2022-2025 59.8 Adjusted* EBITDA EBITDA growth driven by: (PLNm) 55.2 52.7 50.5  Growing scale of recurring sales in both 41.6 segments, characterized by attractive 29.8 30.4 31.7 31.7 33.8 margins 24.9 24.9  Increase in sales of equipment used in 10.9 therapy Q1 2022

  6. Slide 6: Group's recurring sales in FY 2022-2025

    Group’s recurring sales in FY 2022-2025 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) 37.5 Drivers: 35.8  Dynamically increasing demand for consumable 35.0 parts and accessories for therapy equipment sold by the Synektik Group 33.2 Revenue from sales of radiopharm

  7. Slide 7: Selected financial data

    Selected financial data PLN 000s Q1 FY 2025 Q1 FY 2024 Sales revenue 227 977 203 128  Cash surplus over financial liabilities amounting to EBIT* 53 972 45 655 nearly PLN 134 million as of December 31, 2025 EBIT margin* 23.7% 22.5% EBITDA* 59 784 50 529 EBITDA margin* 26.2% 24.9%  Nearly PLN 72 mil

  8. Slide 8: Medical equipment and IT solutions

    SYNEKTIK SA Medical equipment and IT solutions Q1 FY 2025 Financial results | Investor presentation 8

  9. Slide 9: Medical equipment and IT solutions: Key information

    Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas:  Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine 

  10. Slide 10: Medical equipment and IT solutions: Financial results

    Medical equipment and IT solutions Financial results (PLN million) Growing business profitabiity 214.1 191.1  12% increase in sales (year-over-year) in Q1 FY 2025, up to PLN 214.1 million  20% increase in EBITDA in Q1 FY 2025, up to PLN 60.6 million, increase in EBITDA segment profitability by 1.8

  11. Slide 11: Backlog and active offers outlook

    Medical equipment and IT solutions Promising outlook for the coming quarters. Sales of medical equipment, orders for implementation and active offers (in PLN million)  Secured orders worth PLN 148 million in Q1 FY 2025  The value of active offers as of the end of December 2025 is PLN 165.9 million

  12. Slide 12: Commercialization of da Vinci system

    Medical equipment and IT solutions Commercialization of da Vinci system Da Vinci assisted surgical procedures in Poland, Czech Republic and Slovakia (number) 10000 122 9000  Approximately 5.7 k surgeries with the assistance of da Vinci in Q1 FY 2025 in Poland (up 38% y/y) 8000  Approximately 3.4 k

  13. Slide 13: Da Vinci systems serviced by Synektik

    Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Gdańsk Grudziądz Wejherowo Słupsk Olsztyn 122 84 Szczecin Białystok Bydgoszcz Toruń Wieliszew Biała Podlaska Grodzisk da Vinci systems serviced da Vinci systems Gorzów Wlkp. Maz. by GK Synektik in Poland* Poznań Warszawa Sied

  14. Slide 14: Extension and expansion of the agreement with Intuitive – Ukraine

    Medical equipment and IT solutions Extension and expansion of the agreement with Intuitive Ukraina – market potential  Extension of the collaboration agreement with Intuitive through Polska Ukraina 31 December 2031  Expansion of the territorial scope of the agreement with Intuitive to include Popu

  15. Slide 15: Agreement with HistoSonics – Edison system

    Medical equipment and IT solutions Agreement with HistoSonics – expansion of the offering with breakthrough cancer therapy technology  Execution of a cooperation agreement with HistoSonics for the distribution of the Edison systems:  The Group has become the exclusive distributor in Poland, the Cz

  16. Slide 16: Radiopharmaceuticals

    SYNEKTIK SA Radiopharmaceuticals Q1 FY 2025 Financial results | Investor presentation 16

  17. Slide 17: Radiopharmaceuticals: Key information

    Radiopharmaceuticals Key information  Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 55+ Number of 3 Production sites together employees with R&D Centre  Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac

  18. Slide 18: Radiopharmaceuticals: Growing revenues and profits

    Radiopharmaceuticals Growing revenues and profits Financial results (PLN million)  PLN 13.9 million in revenue in Q1 FY 2024, up 15% YoY 13,9 12.1  28% growth in basic tracer sales, to all-time high PLN 7.4 million  3% growth in special tracer sales, to PLN 2.6 million 3.9 4.1  PLN 4.1 million E

  19. Slide 19: Cardiac-tracer

    SYNEKTIK SA Cardiac-tracer Q1 FY 2025 Financial results | Investor presentation 19

  20. Slide 20: Synektik S.A. spin-off plan

    Synektik S.A. spin-off plan  On July 23, 2025, the management boards of Synektik SA and Syn2bio SA agreed on and adopted a plan to divide Synektik SA into two independent publicly listed entities: Cardiac-tracer  To Syn2bio SA, in exchange for shares of a new issue, a part of Synektik SA’s busines

  21. Slide 21: Dividends

    SYNEKTIK SA Dividends Q1 FY 2025 Financial results | Investor presentation 21

  22. Slide 22: Dividends

    Dividends ▪ Resolutions of the Company’s General Meeting regarding profit Synektik S.A. distribution: Dividend history 10.75 ▪ allocation of PLN 91.69 million, representing 99.7% of the Company’s standalone net profit, for dividend payment, in the 8.25 amount of PLN 10.75 per share 102.6 ▪ The divid

  23. Slide 23: Q&A SESSION

    SYNEKTIK SA Q&A SESSION Q1 FY 2025 Financial results | Investor presentation 23

  24. Slide 24: Thank you!

    Cezary Kozanecki Thank you! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl

Synektik — Q1 FY2025 Earnings Presentation on 6ix